Aptose Biosciences Inc. (APTO) Given Consensus Rating of “Buy” by Analysts
Aptose Biosciences Inc. (NASDAQ:APTO) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $12.67.
Several research analysts have commented on APTO shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Aptose Biosciences in a research note on Saturday, June 25th. Zacks Investment Research lowered shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. RBC Capital Markets reaffirmed an “outperform” rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research note on Saturday. Finally, Roth Capital reiterated a “buy” rating and set a $8.00 target price on shares of Aptose Biosciences in a research report on Friday.
Aptose Biosciences (NASDAQ:APTO) traded down 7.3409% during mid-day trading on Tuesday, hitting $2.0385. 67,934 shares of the stock were exchanged. The stock’s market cap is $26.28 million. Aptose Biosciences has a 52-week low of $1.92 and a 52-week high of $6.40. The stock has a 50 day moving average of $2.22 and a 200-day moving average of $2.46.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences as of its most recent filing with the SEC. Institutional investors own 19.47% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.